Pegasus Partners Ltd. grew its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 2.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,668 shares of the company’s stock after buying an additional 290 shares during the quarter. Pegasus Partners Ltd.’s holdings in Merck & were worth $812,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Perennial Advisors LLC grew its stake in shares of Merck & by 10.7% during the second quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after buying an additional 157 shares during the last quarter. Stelac Advisory Services LLC bought a new position in shares of Merck & during the second quarter valued at about $104,000. Vigilant Capital Management LLC grew its stake in shares of Merck & by 16.7% during the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after buying an additional 250 shares during the last quarter. Cascade Investment Advisors Inc. grew its stake in shares of Merck & by 15.5% during the second quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after buying an additional 232 shares during the last quarter. Finally, Solaris Asset Management LLC grew its stake in shares of Merck & by 6.3% during the second quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after buying an additional 115 shares during the last quarter. 72.84% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Merck & Company, Inc. (MRK) opened at $55.87 on Tuesday. The company has a quick ratio of 1.21, a current ratio of 1.50 and a debt-to-equity ratio of 0.55. Merck & Company, Inc. has a 1-year low of $54.41 and a 1-year high of $66.80. The company has a market cap of $153,333.28, a PE ratio of 14.41, a price-to-earnings-growth ratio of 2.41 and a beta of 0.78.

Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.08. Merck & had a net margin of 11.60% and a return on equity of 26.82%. The business had revenue of $10.33 billion during the quarter, compared to analyst estimates of $10.54 billion. During the same period last year, the business posted $1.07 earnings per share. Merck &’s quarterly revenue was down 2.0% compared to the same quarter last year. equities analysts anticipate that Merck & Company, Inc. will post 3.95 EPS for the current fiscal year.

A number of research analysts have recently issued reports on MRK shares. BidaskClub cut Merck & from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Deutsche Bank AG reaffirmed a “hold” rating and set a $66.00 price objective (up from $64.00) on shares of Merck & in a research note on Monday, July 17th. BMO Capital Markets reaffirmed an “outperform” rating and set a $73.00 price objective (down from $74.00) on shares of Merck & in a research note on Monday, July 24th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $74.00 price objective (up from $70.00) on shares of Merck & in a research note on Thursday, July 27th. Finally, Piper Jaffray Companies set a $70.00 price objective on Merck & and gave the company a “buy” rating in a research note on Saturday, July 29th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $67.07.

ILLEGAL ACTIVITY NOTICE: “Pegasus Partners Ltd. Buys 290 Shares of Merck & Company, Inc. (MRK)” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/pegasus-partners-ltd-buys-290-shares-of-merck-company-inc-mrk/1684425.html.

Merck & Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.